Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

XENON PHARMACEUTICALS INC.

(XENE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
28.99(c) 27.13(c) 28.07(c) 28.19(c) 27.44(c) Last
688 914 710 274 415 376 289 096 383 799 Volume
-0.99% -6.42% +3.46% +0.43% -2.66% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 22,0 M - -
Net income 2021 -69,0 M - -
Net cash position 2021 545 M - -
P/E ratio 2021 -16,9x
Yield 2021 -
Sales 2022 12,9 M - -
Net income 2022 -101 M - -
Net cash position 2022 475 M - -
P/E ratio 2022 -13,9x
Yield 2022 -
Capitalization 1 416 M 1 416 M -
EV / Sales 2021 39,6x
EV / Sales 2022 73,0x
Nbr of Employees 126
Free-Float 93,8%
More Financials
Company
Xenon Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing therapeutics in patients with neurological disorders. Its product candidates include XEN1101, XEN496 and XEN007. Its partnered programs include NBI-921352 and FX301. Its XEN1101is a Kv7 potassium channel modulator for the treatment of epilepsy and other neurological disorders. Its XEN496 is a Kv7 potassium... 
More about the company
Ratings of Xenon Pharmaceuticals Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about XENON PHARMACEUTICALS INC.
11/12Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
AQ
11/11SVB Leerink Adjusts Xenon Pharmaceuticals' Price Target to $40 from $34, Keeps Outperfo..
MT
11/10Xenon Pharma Posts Mixed Q3 Results vs Street Estimates, Sees Enough Funds Till 2024
MT
11/10XENON PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
11/10Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corpora..
PU
11/10Earnings Flash (XENE) XENON PHARMACEUTICALS Posts Q3 Revenue $8.12M, vs. Street Est of ..
MT
11/10XENON PHARMACEUTICALS : Q3 Earnings Snapshot
AQ
11/10Earnings Flash (XENE) XENON PHARMACEUTICALS Posts Q3 Revenue $8.1M, vs. Street Est of $..
MT
11/10Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corpora..
AQ
11/10Xenon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/04Certain Warrants of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Endi..
CI
11/04Certain Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending..
CI
11/04Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement ..
CI
11/03Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 20..
AQ
10/28RBC Initiates Xenon Pharmaceuticals at Outperform With Speculative Risk, Sets Price Tar..
MT
More news
News in other languages on XENON PHARMACEUTICALS INC.
11/10Xenon Pharma affiche des résultats mitigés au troisième trimestre par rapport aux estim..
11/10Earnings Flash (XENE) XENON PHARMACEUTICALS affiche un chiffre d'affaires de 8,12 milli..
11/10Earnings Flash (XENE) XENON PHARMACEUTICALS affiche un chiffre d'affaires de 8,1 millio..
10/08Xenon Pharmaceuticals clôture son offre publique de vente et lève 345 millions de dolla..
10/06Xenon Pharmaceuticals propose une offre d'actions pour 300 millions de dollars
More news
Analyst Recommendations on XENON PHARMACEUTICALS INC.
More recommendations
Chart XENON PHARMACEUTICALS INC.
Duration : Period :
Xenon Pharmaceuticals Inc. Technical Analysis Chart | XENE | CA98420N1050 | MarketScreener
Technical analysis trends XENON PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 27,44 $
Average target price 45,70 $
Spread / Average Target 66,5%
EPS Revisions
Managers and Directors
Ian C. Mortimer President, Chief Executive Officer & Director
Sherry Aulin Chief Financial Officer
Simon Neil Pimstone Executive Chairman
Sheila M. Grant Senior VP-Research & Development Operations
Christopher Kenney Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
XENON PHARMACEUTICALS INC.78.41%1 416
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678